GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Current Deferred Revenue

NKGen Biotech (NKGen Biotech) Current Deferred Revenue : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

NKGen Biotech's current deferred revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

NKGen Biotech Current Deferred Revenue Historical Data

The historical data trend for NKGen Biotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Current Deferred Revenue Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Current Deferred Revenue
- - -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

NKGen Biotech Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.